table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
anticoagulant Paranjpe X-COVID-19
anticoagulant, curative dose COALIZAO ACTION Bousquet Bousquet ATTACC, ACTIV-4a, and REMAP-CAP ... COVID-PACT REMAP-CAP, ACTIV-4a, ATTACC ...
anticoagulant, prophylactic dose Bousquet Bousquet Tang
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ... ATTACC ... REMAP-CAP Anticoagulation ACTIV-4a ...

0 studies excluded by filtering options 2

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons